[
  {
    "ts": null,
    "headline": "Amgen (AMGN) Valuation Check After FDA Expansion of UPLIZNA in Generalized Myasthenia Gravis",
    "summary": "Amgen (AMGN) just picked up a meaningful FDA win, with UPLIZNA cleared for a specific subset of adults with generalized myasthenia gravis, expanding both the drug’s addressable market and the company’s autoimmune footprint. See our latest analysis for Amgen. The UPLIZNA approval lands at a time when momentum in Amgen’s stock is quietly building, with the recent autoimmune wins, orphan drug progress and a dividend hike helping underpin an 18.94% 3 month share price return and a 5 year total...",
    "url": "https://finnhub.io/api/news?id=13eee5502ca6624bab7317159b4a1bd297dec937990a3945e2ac1e61acd0011c",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1766009274,
      "headline": "Amgen (AMGN) Valuation Check After FDA Expansion of UPLIZNA in Generalized Myasthenia Gravis",
      "id": 137817145,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "AMGN",
      "source": "Yahoo",
      "summary": "Amgen (AMGN) just picked up a meaningful FDA win, with UPLIZNA cleared for a specific subset of adults with generalized myasthenia gravis, expanding both the drug’s addressable market and the company’s autoimmune footprint. See our latest analysis for Amgen. The UPLIZNA approval lands at a time when momentum in Amgen’s stock is quietly building, with the recent autoimmune wins, orphan drug progress and a dividend hike helping underpin an 18.94% 3 month share price return and a 5 year total...",
      "url": "https://finnhub.io/api/news?id=13eee5502ca6624bab7317159b4a1bd297dec937990a3945e2ac1e61acd0011c"
    }
  },
  {
    "ts": null,
    "headline": "HSBC Turns More Bullish on Amgen (AMGN) into 2026",
    "summary": "Amgen Inc. (NASDAQ:AMGN) is included among the 12 Best Dogs of the Dow to Invest in. On December 8, HSBC lifted its price target on Amgen Inc. (NASDAQ:AMGN) to $425 from $381. The firm also retained a Buy rating. The call came as part of the firm’s 2026 outlook for the pharma sector. HSBC sees […]",
    "url": "https://finnhub.io/api/news?id=d48ee2820bd55f0972dd0601d2c13acd350f45dd3f3938f42e145716cecf6bdf",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1765998964,
      "headline": "HSBC Turns More Bullish on Amgen (AMGN) into 2026",
      "id": 137817146,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "AMGN",
      "source": "Yahoo",
      "summary": "Amgen Inc. (NASDAQ:AMGN) is included among the 12 Best Dogs of the Dow to Invest in. On December 8, HSBC lifted its price target on Amgen Inc. (NASDAQ:AMGN) to $425 from $381. The firm also retained a Buy rating. The call came as part of the firm’s 2026 outlook for the pharma sector. HSBC sees […]",
      "url": "https://finnhub.io/api/news?id=d48ee2820bd55f0972dd0601d2c13acd350f45dd3f3938f42e145716cecf6bdf"
    }
  },
  {
    "ts": null,
    "headline": "SCHD: This ETF Stinks",
    "summary": "Read why the SCHD ETF remains a stable choice for dividend growth, despite recent AI-driven underperformance.",
    "url": "https://finnhub.io/api/news?id=3b6d2a33cb106d0d459e3c8cce8bbdbf79f04cd264a88033ffe937ea315f9e5d",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1765997441,
      "headline": "SCHD: This ETF Stinks",
      "id": 137814928,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1364623580/image_1364623580.jpg?io=getty-c-w1536",
      "related": "AMGN",
      "source": "SeekingAlpha",
      "summary": "Read why the SCHD ETF remains a stable choice for dividend growth, despite recent AI-driven underperformance.",
      "url": "https://finnhub.io/api/news?id=3b6d2a33cb106d0d459e3c8cce8bbdbf79f04cd264a88033ffe937ea315f9e5d"
    }
  },
  {
    "ts": null,
    "headline": "Investors Heavily Search Amgen Inc. (AMGN): Here is What You Need to Know",
    "summary": "Zacks.com users have recently been watching Amgen (AMGN) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.",
    "url": "https://finnhub.io/api/news?id=67a77af9abf7cebabeb8ff2817565e0e04f90b7c74affe80a650b8a831ea85d9",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1765980003,
      "headline": "Investors Heavily Search Amgen Inc. (AMGN): Here is What You Need to Know",
      "id": 137817147,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "AMGN",
      "source": "Yahoo",
      "summary": "Zacks.com users have recently been watching Amgen (AMGN) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.",
      "url": "https://finnhub.io/api/news?id=67a77af9abf7cebabeb8ff2817565e0e04f90b7c74affe80a650b8a831ea85d9"
    }
  }
]